HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Celcuity breast cancer drug misses 'lofty' expectations in ASCO-spotlighted trial

Gedatolisib could "establish a new standard of care" for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

By BioPharma Dive · Jun 2, 2026 · via BioPharma Dive
Celcuity breast cancer drug misses 'lofty' expectations in ASCO-spotlighted trial

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
The WeekFiercePharma ↗
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
Jun 3, 2026
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
The WeekFierceBiotech ↗
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-r…
Jun 3, 2026
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The WeekBriefing
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…
Jun 3, 2026